
Sign up to save your podcasts
Or


This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.
By BioSpace4.9
1313 ratings
This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.

91,103 Listeners

30,738 Listeners

43,542 Listeners

8,780 Listeners

977 Listeners

4,390 Listeners

1,175 Listeners

1,989 Listeners

56,865 Listeners

9,559 Listeners

337 Listeners

6,131 Listeners

6,579 Listeners

34 Listeners

21 Listeners